BNTX vs. ICLR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BNTX and ICLR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, ICLR is a standard domestic listing.
| Symbol | BNTX | ICLR |
|---|---|---|
| Company Name | BioNTech SE | ICON Public Limited Company |
| Country | Germany | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 27.11 billion USD | 13.71 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | October 10, 2019 | May 15, 1998 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of BNTX and ICLR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BNTX | ICLR |
|---|---|---|
| 5-Day Price Return | 1.28% | 11.68% |
| 13-Week Price Return | 15.95% | 25.72% |
| 26-Week Price Return | -5.97% | -10.03% |
| 52-Week Price Return | 39.89% | -43.45% |
| Month-to-Date Return | 4.91% | 4.20% |
| Year-to-Date Return | -1.03% | -15.94% |
| 10-Day Avg. Volume | 0.77M | 1.14M |
| 3-Month Avg. Volume | 1.02M | 1.56M |
| 3-Month Volatility | 46.79% | 59.84% |
| Beta | 1.53 | 1.25 |
Profitability
Return on Equity (TTM)
BNTX
-3.43%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
BNTX has a negative Return on Equity of -3.43%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
ICLR
8.28%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
ICLR’s Return on Equity of 8.28% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BNTX
-24.18%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
BNTX has a negative Net Profit Margin of -24.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
ICLR
9.82%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
ICLR’s Net Profit Margin of 9.82% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BNTX
-47.77%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
BNTX has a negative Operating Profit Margin of -47.77%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
ICLR
12.50%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
ICLR’s Operating Profit Margin of 12.50% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BNTX | ICLR |
|---|---|---|
| Return on Equity (TTM) | -3.43% | 8.28% |
| Return on Assets (TTM) | -2.98% | 4.71% |
| Net Profit Margin (TTM) | -24.18% | 9.82% |
| Operating Profit Margin (TTM) | -47.77% | 12.50% |
| Gross Profit Margin (TTM) | 84.90% | 28.65% |
Financial Strength
Current Ratio (MRQ)
BNTX
7.45
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BNTX’s Current Ratio of 7.45 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ICLR
1.29
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
ICLR’s Current Ratio of 1.29 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BNTX
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ICLR
0.36
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
ICLR’s Debt-to-Equity Ratio of 0.36 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ICLR
4.80
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
ICLR’s Interest Coverage Ratio of 4.80 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BNTX | ICLR |
|---|---|---|
| Current Ratio (MRQ) | 7.45 | 1.29 |
| Quick Ratio (MRQ) | 7.34 | 1.24 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.36 |
| Interest Coverage Ratio (TTM) | -1.43 | 4.80 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
ICLR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
ICLR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BNTX | ICLR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 17.60% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BNTX
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for BNTX is currently unavailable.
ICLR
17.04
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/E Ratio of 17.04 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BNTX
8.27
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
BNTX’s P/S Ratio of 8.27 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ICLR
1.67
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/S Ratio of 1.67 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BNTX
1.20
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BNTX’s P/B Ratio of 1.20 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
ICLR
1.21
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
ICLR’s P/B Ratio of 1.21 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BNTX | ICLR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 17.04 |
| Price-to-Sales Ratio (TTM) | 8.27 | 1.67 |
| Price-to-Book Ratio (MRQ) | 1.20 | 1.21 |
| Price-to-Free Cash Flow Ratio (TTM) | 8.11 | 13.67 |